Novel Therapies for Metabolic Complications of Lipodystrophies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00457938|
Recruitment Status : Unknown
Verified June 2013 by Abhimanyu Garg, University of Texas Southwestern Medical Center.
Recruitment status was: Recruiting
First Posted : April 9, 2007
Last Update Posted : June 21, 2013
University of Texas Southwestern Medical Center
National Institutes of Health (NIH)
Amylin Pharmaceuticals, LLC.
Information provided by (Responsible Party):
Abhimanyu Garg, University of Texas Southwestern Medical Center
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||August 2016|
|Estimated Study Completion Date :||December 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Simha V, Subramanyam L, Szczepaniak L, Quittner C, Adams-Huet B, Snell P, Garg A. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab. 2012 Mar;97(3):785-92. doi: 10.1210/jc.2011-2229. Epub 2011 Dec 14.